Translation of Myocardial Metabolic Imaging Concepts into the Clinics

Cardiology Clinics

Volumn 27, Issue 2, 2009, Pages 291-310

  Bashir, Adil ^a   Gropler, Robert J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fatty acids; Glucose; Heart; Metabolism; Tomography

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; ACETIC ACID C 11; CARBON 13; FLUORINE; FLUORINE 18; FLUORODEOXYGLUCOSE; HYDROGEN; METOPROLOL; NITROGEN 15; PALMITIC ACID C 11; PHOSPHORUS 31; RADIOISOTOPE; SODIUM 23; TETROFOSMIN;

AGING; CARBOHYDRATE METABOLISM; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; ENERGY YIELD; FATTY ACID METABOLISM; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENDER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERTENSION; IMAGING; INSULIN RESISTANCE; ISCHEMIA; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

DIAGNOSIS, DIFFERENTIAL; FATTY ACIDS; GLUCOSE; HEART DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIUM; OXYGEN CONSUMPTION; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 62549095882     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.12.004     Document Type: Review

References (110)

1. Bing R.J. The metabolism of the heart. Harvey Lect 50 (1955) 27-70
2. Neely J.R., and Morgan H.E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 36 (1974) 413-459
3. Goodwin G.W., and Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am J Phys 277 4 Pt 1 (1999) E772-E777
4. McGarry J.D., and Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244 1 (1997) 1-14
5. McGarry J.D., Mannaerts G.P., and Foster D.W. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 60 1 (1977) 265-270
6. Sugden M.C., and Holness M.J. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 284 5 (2003) E855-E862
7. Young M.E., Goodwin G.W., Ying J., et al. Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 280 3 (2001) E471-E479
8. Kelly D.P. PPARs of the heart: three is a crowd. Circ Res 92 5 (2003) 482-484
9. Finck B.N., Han X., Courtois M., et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100 3 (2003) 1226-1231
10. Depre C., Shipley G.L., Chen W., et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4 11 (1998) 1269-1275
11. Szczepaniak L.S., Babcock E.E., Schick F., et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Phys 276 5 Pt 1 (1999) E977-E989
12. Yoshida T. The rate of phosphocreatine hydrolysis and resynthesis in exercising muscle in humans using 31P-MRS. J Physiol Anthropol Appl Human Sci 21 5 (2002) 247-255
13. Lewandowski E.D. Cardiac carbon 13 magnetic resonance spectroscopy: on the horizon or over the rainbow?. J Nucl Cardiol 9 4 (2002) 419-428
14. Bottomley P.A., and Weiss R.G. Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 351 9104 (1998) 714-718
15. He Z.X., Shi R.F., Wu Y.J., et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation 108 10 (2003) 1208-1213
16. DeGrado T.R., Holden J.E., Ng C.K., et al. Quantitative analysis of myocardial kinetics of 15-p-[iodine-125] iodophenylpentadecanoic acid. J Nucl Med 30 7 (1989) 1211-1218
17. Dormehl I.C., Hugo N., Rossouw D., et al. Planar myocardial imaging in the baboon model with iodine-123-15-(iodophenyl)pentadecanoic acid (IPPA) and iodine-123-15-(P-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP), using time-activity curves for evaluation of metabolism. Nucl Med Biol 22 7 (1995) 837-847
18. Eckelman W.C., and Babich J.W. Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution. J Nucl Cardiol 14 Suppl 3 (2007) S100-S109
19. Reske S.N., Sauer W., Machulla H.J., et al. Metabolism of 15 (p 123I iodophenyl-)pentadecanoic acid in heart muscle and noncardiac tissues. Eur J Nucl Med 10 5-6 (1985) 228-234
20. Ambrose K.R., Owen B.A., Goodman M.M., et al. Evaluation of the metabolism in rat hearts of two new radioiodinated 3-methyl-branched fatty acid myocardial imaging agents. Eur J Nucl Med 12 10 (1987) 486-491
21. Goodman M.M., Kirsch G., and Knapp Jr. F.F. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-substituted alpha- and beta-methyl-branched fatty acids. J Med Chem 27 3 (1984) 390-397
22. Iida H., Rhodes C.G., Araujo L.I., et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans. Circulation 94 4 (1996) 792-807
23. Laine H., Katoh C., Luotolahti M., et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation 100 24 (1999) 2425-2430
24. Yamamoto Y., de Silva R., Rhodes C.G., et al. Noninvasive quantification of regional myocardial metabolic rate of oxygen by 15O2 inhalation and positron emission tomography. Experimental validation. Circulation 94 4 (1996) 808-816
25. Armbrecht J.J., Buxton D.B., and Schelbert H.R. Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 81 5 (1990) 1594-1605
26. Brown M., Marshall D.R., Sobel B.E., et al. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation 76 3 (1987) 687-696
27. Brown M.A., Myears D.W., and Bergmann S.R. Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol 12 4 (1988) 1054-1063
28. Buck A., Wolpers H.G., Hutchins G.D., et al. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med 32 10 (1991) 1950-1957
29. Sun K.T., Yeatman L.A., Buxton D.B., et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 39 2 (1998) 272-280
30. Choi Y., Hawkins R.A., Huang S.C., et al. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies. J Nucl Med 32 4 (1991) 733-738
31. Gambert S., Vergely C., Filomenko R., et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 283 1-2 (2006) 147-152
32. Iozzo P., Chareonthaitawee P., Di Terlizzi M., et al. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab 282 5 (2002) E1163-E1171
33. Krivokapich J., Huang S.C., Selin C.E., et al. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Phys 252 4 Pt 2 (1987) H777-H787
34. Botker H.E., Bottcher M., Schmitz O., et al. Glucose uptake and lumped constant variability in normal human hearts determined with [18F]fluorodeoxyglucose. J Nucl Cardiol 4 2 Pt 1 (1997) 125-132
35. Hariharan R., Bray M., Ganim R., et al. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation 91 9 (1995) 2435-2444
36. Hashimoto K., Nishimura T., Imahashi K.I., et al. Lumped constant for deoxyglucose is decreased when myocardial glucose uptake is enhanced. Am J Phys 276 1 Pt 2 (1999) H129-H133
37. Herrero P., Sharp T.L., Dence C., et al. Comparison of 1-(11)C-glucose and (18)F-FDG for quantifying myocardial glucose use with PET. J Nucl Med 43 11 (2002) 1530-1541
38. Herrero P., Weinheimer C.J., Dence C., et al. Quantification of myocardial glucose utilization by PET and 1-carbon-11-glucose. J Nucl Cardiol 9 1 (2002) 5-14
39. Herrero P., Kisrieva-Ware Z., Dence C.S., et al. PET measurements of myocardial glucose metabolism with 1-11C-glucose and kinetic modeling. J Nucl Med 48 6 (2007) 955-964
40. Herrero P., Dence C.S., Coggan A.R., et al. L-3-11C-lactate as a PET tracer of myocardial lactate metabolism: a feasibility study. J Nucl Med 48 12 (2007) 2046-2055
41. Bergmann S.R., Weinheimer C.J., Markham J., et al. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 37 10 (1996) 1723-1730
42. Davila-Roman V.G., Vedala G., Herrero P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40 2 (2002) 271-277
43. Herrero P., Peterson L.R., McGill J.B., et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47 3 (2006) 598-604
44. Peterson L.R., Herrero P., Schechtman K.B., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 18 (2004) 2191-2196
45. DeGrado T.R. Synthesis of 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA). J Labelled Comp Radiopharm 29 (1991) 989-995
46. DeGrado T.R., Coenen H.H., and Stocklin G. 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med 32 10 (1991) 1888-1896
47. Schulz G., von Dahl J., Kaiser H.J., et al. Imaging of beta-oxidation by static PET with 14(R,S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease: a comparison with 18FDG-PET and 99Tcm-MIBI SPET. Nucl Med Commun 17 12 (1996) 1057-1064
48. Taylor M., Wallhaus T.R., Degrado T.R., et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 42 1 (2001) 55-62
49. DeGrado T.R., Wang S., Holden J.E., et al. Synthesis and preliminary evaluation of (18)F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation. Nucl Med Biol 27 3 (2000) 221-231
50. DeGrado T.R., Kitapci M.T., Wang S., et al. Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: effects of hypoxia and composition of exogenous fatty acids. J Nucl Med 47 1 (2006) 173-181
51. Shoup T.M., Elmaleh D.R., Bonab A.A., et al. Evaluation of trans-9-18F-fluoro-3,4-Methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 46 2 (2005) 297-304
52. Desrois M., Sidell R.J., Gauguier D., et al. Gender differences in hypertrophy, insulin resistance and ischemic injury in the aging type 2 diabetic rat heart. J Mol Cell Cardiol 37 2 (2004) 547-555
53. Dyck J.R., and Lopaschuk G.D. Glucose metabolism, H+ production and Na+/H+-exchanger mRNA levels in ischemic hearts from diabetic rats. Mol Cell Biochem 180 1-2 (1998) 85-93
54. Peterson L.R., Soto P.F., Herrero P., et al. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol 14 4 (2007) 573-581
55. Peterson L.R., Soto P.M., Herrero P., et al. Impact of gender on the myocardial metabolic response to obesity. JACC CU Imag 1 (2008) 424-433
56. Abu-Erreish G.M., Neely J.R., Whitmer J.T., et al. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Phys 232 3 (1977) E258-E262
57. McMillin J.B., Taffet G.E., Taegtmeyer H., et al. Mitochondrial metabolism and substrate competition in the aging Fischer rat heart. Cardiovasc Res 27 12 (1993) 2222-2228
58. Iemitsu M., Miyauchi T., Maeda S., et al. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 283 5 (2002) H1750-H1760
59. Odiet J.A., Boerrigter M.E., and Wei J.Y. Carnitine palmityl transferase-I activity in the aging mouse heart. Mech Ageing Dev 79 2-3 (1995) 127-136
60. Paradies G., Ruggiero F.M., Gadaleta M.N., et al. The effect of aging and acetyl-L-carnitine on the activity of the phosphate carrier and on the phospholipid composition in rat heart mitochondria. Biochim Biophys Acta 1103 2 (1992) 324-326
61. Kates A.M., Herrero P., Dence C., et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 41 (2003) 293-299
62. Soto P.F., Herrero P., Kates A.M., et al. Impact of aging on myocardial metabolic response to dobutamine. Am J Physiol Heart Circ Physiol 285 (2003) 2158-2164
63. Soto P.F., Herrero P., Schechtman K.B., et al. Exercise training impacts the myocardial metabolism of older individuals in a gender-specific manner. Am J Physiol Heart Circ Physiol 295 2 (2008) H842-H850
64. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 139 2 Pt 3 (2000) S115-S119
65. Araujo L.I., Camici P., Spinks T.J., et al. Abnormalities in myocardial metabolism in patients with unstable angina as assessed by positron emission tomography. Cardiovasc Drugs Ther 2 1 (1988) 41-46
66. Camici P., Araujo L.I., Spinks T., et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation 74 1 (1986) 81-88
67. Kawai Y., Tsukamoto E., Nozaki Y., et al. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 38 7 (2001) 1888-1894
68. Tamaki N. Role of BMIPP imaging for risk stratification in patients with coronary artery disease. J Nucl Cardiol 12 2 (2005) 148-150
69. Barger P.M., and Kelly D.P. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318 1 (1999) 36-42
70. Rupp H., and Jacob R. Metabolically-modulated growth and phenotype of the rat heart. Eur Heart J 13 Suppl D (1992) 56-61
71. Blair E., Redwood C., Ashrafian H., et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10 11 (2001) 1215-1220
72. Jamshidi Y., Montgomery H.E., Hense H.W., et al. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105 8 (2002) 950-955
73. Handa N., Magata Y., Mukai T., et al. Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo. Ann Nucl Med 21 10 (2007) 569-576
74. de las Fuentes L., Herrero P., Peterson L.R., et al. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension 41 1 (2003) 83-87
75. de las Fuentes L., Soto P.F., Cupps B.P., et al. Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol 13 3 (2006) 369-377
76. Tuunanen H., Kuusisto J., Toikka J., et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol 14 3 (2007) 354-365
77. Buttrick P.M., Kaplan M., Leinwand L.A., et al. Alterations in gene expression in the rat heart after chronic pathological and physiological loads. J Mol Cell Cardiol 26 1 (1994) 61-67
78. Sack M.N., and Kelly D.P. The energy substrate switch during development of heart failure: gene regulatory mechanisms. [Review]. Int J Mol Med 1 1 (1998) 17-24
79. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 110 8 (2004) 894-896
80. Nakae I., Matsuo S., Koh T., et al. Iodine-123 BMIPP scintigraphy in the evaluation of patients with heart failure. Acta Radiol 47 8 (2006) 810-816
81. Tuunanen H., Engblom E., Naum A., et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 12 8 (2006) 644-652
82. 1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 102 (2000) 2070-2075
83. Stolen K.Q., Kemppainen J., Ukkonen H., et al. Exercise training improves biventricular oxidative metabolism and left ventricular efficiency in patients with dilated cardiomyopathy. J Am Coll Cardiol 41 3 (2003) 460-467
84. Sundell J., Engblom E., Koistinen J., et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 43 6 (2004) 1027-1033
85. Nowak B., Sinha A.M., Schaefer W.M., et al. Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. J Am Coll Cardiol 41 9 (2003) 1523-1528
86. Tuunanen H., Engblom E., Naum A., et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 12 (2008) 1250-1258
87. Hasegawa S., Kusuoka H., Maruyama K., et al. Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers. J Am Coll Cardiol 43 2 (2004) 224-233
88. van Campen C.M., Visser F.C., van der Weerdt A.P., et al. FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging 34 3 (2007) 309-315
89. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974) 29-34
90. Stanley W.C., Lopaschuk G.D., and McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34 1 (1997) 25-33
91. Rodrigues B., Cam M.C., and McNeill J.H. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27 (1995) 169-179
92. Taegtmeyer H., McNulty P., and Young M.E. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105 14 (2002) 1727-1733
93. Young M.E., McNulty P., and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 105 15 (2002) 1861-1870
94. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109 1 (2002) 121-130
95. Burkart E.M., Sambandam N., Han X., et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 117 12 (2007) 3930-3939
96. Shoghi K.I., Gropler R.J., Sharp T., et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med 49 8 (2008) 1320-1327
97. Welch M.J., Lewis J.S., Kim J., et al. Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. J Nucl Med 47 4 (2006) 689-697
98. Monti L.D., Landoni C., Setola E., et al. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients. Am J Physiol Heart Circ Physiol 287 3 (2004) H1225-H1231
99. Monti L.D., Lucignani G., Landoni C., et al. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels. Diabetes 44 5 (1995) 537-542
100. vom Dahl J., Herman W.H., Hicks R.J., et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation 88 2 (1993) 395-404
101. Avogaro A., Nosadini R., Doria A., et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Phys 258 4 Pt 1 (1990) E606-E618
102. Herrero P., McGill J.B., Lesniak D., et al. PET detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus. J Nucl Cardiol 15 6 (2008) 598-604
103. Peterson L.R., Herrero P., McGill J., et al. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes 57 1 (2008) 32-40
104. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97 4 (2000) 1784-1789
105. Hallsten K., Virtanen K.A., Lonnqvist F., et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 21 12 (2004) 1280-1287
106. Commerford S.R., Pagliassotti M.J., Melby C.L., et al. Fat oxidation, lipolysis, and free fatty acid cycling in obesity-prone and obesity-resistant rats. Am J Physiol Endocrinol Metab 279 4 (2000) E875-E885
107. Ogawa M., Ishino S., Mukai T., et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 45 7 (2004) 1245-1250
108. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105 23 (2002) 2708-2711
109. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48 9 (2006) 1825-1831
110. Tawakol A., Migrino R.Q., Bashian G.G., et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48 9 (2006) 1818-1824